Navigation Links
Archimedes Pharma Announces Successful Proof-of-Concept Results on Two Intranasal Development Projects
Date:2/26/2009

ited which also developed PecSys(TM), the proprietary technology which underpins NasalFent.

Dr Alan Smith, VP Research & Development, at Archimedes, commented: "These results illustrate the expertise at Archimedes in taking well characterized therapeutic compounds such as apomorphine and diazepam and creating innovative, tangible products with clear potential advantages over currently marketed agents. We look forward to taking these exciting therapeutics into further trials."

Archimedes will now begin preparations to take both IN Apomorphine and IN Diazepam into further clinical trials and management anticipates the initiation of Phase II studies later in 2009. If development proceeds to plan, both IN Apomorphine and IN Diazepam could be approved in 2012.

IN Apomorphine - trial design, results and development rationale

The pharmacokinetics (PK) and safety/tolerability of Archimedes' IN Apomorphine formulation (3.5 mg dose), compared with a commercial subcutaneous (SC) injection (2 mg dose), were demonstrated in a Phase I proof of principle study in 12 healthy volunteers. IN Apomorphine was well and reproducibly absorbed via the nasal route with therapeutically relevant plasma concentrations reached within 10 minutes of administration. The product showed good nasal tolerability and systemic adverse effects were comparable to those after SC injection and typical of adverse effects that commonly occur in apomorphine naïve individuals. The significant and reproducible plasma levels with IN Apomorphine are consistent with a potential for rapid treatment of hypomobility in advanced Parkinson's disease (PD) and illustrate the product's potential to replace apomorphine injections.

Apomorphine, a potent dopamine agonist, is currently the only drug approved specifically for the treatment of acute motor fluctuations/hypomobility (freezing or "off" episodes) in patients with advanc
'/>"/>

SOURCE Archimedes Pharma Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Adlyfe Strikes Translational Medicine Partnership With Wyeth Pharmaceuticals for Alzheimers Biomarker Assay
2. MAP Pharmaceuticals Announces Phase 3 Study of Unit Dose Budesonide in Children With Asthma Did Not Meet Primary Endpoints
3. AstraZenecas Partner, MAP Pharmaceuticals, Announces Phase 3 Study of Unit Dose Budesonide in Children with Asthma Did Not Meet Primary Endpoints
4. Cordex Pharma Announces Strategic Master Services Equity Agreement With Cato BioVentures
5. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
6. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
7. Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
8. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
9. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
10. Endo Pharmaceuticals Announces Research Collaborations to Develop Novel Pain Treatments and Discover Potential Cancer Treatments
11. Sequoia Pharmaceuticals Presents Proof of Clinical Concept of SPI-452, a Novel Pharmacokinetic Enhancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... July 30, 2015 EnteroMedics Inc. (NASDAQ: ... technology to treat obesity, metabolic diseases and other gastrointestinal ... call on Thursday, August 6, 2015, at 11:00 AM ... quarter ended June 30, 2015, and to provide an ... Therapy, delivered via the Maestro® System. Conference ...
(Date:7/30/2015)... , July 30, 2015 ... "The Group") the regenerative medical devices company, announces ... the post-acute wound care market as Tissue Regenix ... DermaPure® under Medicare administrator, First Coast Service Options ... Florida , Puerto Rico ...
(Date:7/30/2015)... 2015 ReportsnReports.com adds ... tumor biomarker tests, imaging, endoscopy and biopsy ... global industry by technology and application. ... Biomarker Tests, Imaging, Endoscopy and Biopsy) Report ... 9 companies and supported with 180 tables ...
Breaking Medicine Technology:EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 2EnteroMedics to Host Second Quarter 2015 Financial Results and Company Update Conference Call 3Tissue Regenix Group plc: First Coast Service Options Inc. Approves Medicare Coverage for DermaPure 2Tissue Regenix Group plc: First Coast Service Options Inc. Approves Medicare Coverage for DermaPure 3Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 2Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 3Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 4Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 5Cancer Diagnostics Market to see 12% CAGR to 2020: Analysis of Tumor Biomarker Tests, Imaging, Endoscopy, Biopsy and More in New Research Reports 6
... 24, 2011 Molecular Devices, Inc. and ChanTest Corporation, ... tools and solutions, have signed an agreement for Molecular ... and GPCR cell lines on a non-exclusive basis.  As ... ChanTest,s ion channel and GPCR cell lines and promote ...
... MELVILLE, N.Y., March 24, 2011 Henry Schein, Inc. ... health care products and services to office-based dental, medical ... the "Wholesalers:  Health Care" industry in Fortune ... the categories of Social Responsibility and Global Competitiveness.  The ...
Cached Medicine Technology:Molecular Devices, Inc. and ChanTest Corporation Sign Cell Line Distribution Agreement 2Molecular Devices, Inc. and ChanTest Corporation Sign Cell Line Distribution Agreement 3Henry Schein Ranks #1 in Its Industry for Social Responsibility as a Fortune 2011 World's Most Admired Company 2Henry Schein Ranks #1 in Its Industry for Social Responsibility as a Fortune 2011 World's Most Admired Company 3
(Date:7/30/2015)... ... July 30, 2015 , ... On July 23rd Clay Today Online ... to fund the state’s large prison system, which has amassed largely enough throughout the ... incarceration. In light of President Obama’s recent reduction of non violent drug offender’s prison ...
(Date:7/30/2015)... ... , ... Gummy smile surgeon, Dr. Alex Farnoosh, now offers comprehensive ... as the patented gum depigmentation treatmet. Dr. Farnoosh is a renowned dentist with decades ... around the world. , “Like treatment of any other disease or condition, making the ...
(Date:7/30/2015)... ... 30, 2015 , ... New research finds some distinct differences in the way ... on the Surviving Mesothelioma website. , Researchers with the National Institutes of Health, ... cases of mesothelioma occurring between 1990 and 2010. Two percent of these cases (207) ...
(Date:7/30/2015)... ... , ... Author Dr. Raul Llanos seeks to empower readers to ... book, “ Consciously Healing our Webs of Health, Wellbeing, Success, and Abundance ” (published ... responsibility for ourselves, we can create better realities.” His book illustrates the possibilities of ...
(Date:7/30/2015)... ... , ... After a three year trial designed to study the efficiency and ... “bionic eye,” researchers have determined the trial to be a success, and are recommending ... affected by complete vision loss as a result of Retinitis pigmentosa. The results of ...
Breaking Medicine News(10 mins):Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 2Health News:Florida Questions Its Spending on Punitive Incarceration in Light of Exorbitant Costs for Non Violent Offenders 3Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2Health News:Study Finds Mesothelioma Behaves Differently in Younger People, According to Surviving Mesothelioma 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 2Health News:New book by Dr. Raul Llanos: ‘The power to change is within’ 3Health News:The Vision Enhancing “Bionic Eye” Deemed Safe For Long Term Use After Three Year Clinical Trial 2
... common cancer drug imatinib (Gleevec), researchers have eliminated morphine ... the effectiveness of chronic pain management in patients, according ... Cancer Center. Narcotics such as morphine are a ... the pain-relieving effects of these drugs can develop, requiring ...
... caused by an erosion of the protective caps on chromosomes, ... allows malignant cells to evade destruction and acquire more deadly ... journal Cell . In a strain of ... through this two-step process developed lethal cancer and 25 percent ...
... A Cedars-Sinai research scientist has been awarded two ... prestigious Research Project Grant from the National Institutes of ... Terrence Town, PhD, is studying drugs that ... amyloid plaques that build up in the brain and ...
... HealthDay Reporter , MONDAY, Feb. 20 (HealthDay News) -- Alcohol ... new national survey reveals. The online, anonymous poll indicated ... abuse or dependence: nearly 14 percent of male surgeons and ... 8 percent to 12 percent figure typically cited for alcohol ...
... Institute researchers will lead a symposium on relationships between ... autism in children during the American Association for the ... in Vancouver, Canada. The symposium, "Autism: Genetic, Epigenetic ... Feb. 18. The researchers, both affiliated with the UC ...
... Alzheimer,s disease drugs now being tested in clinical trials ... Northwestern Medicine research. A study with mice suggests the ... to be miswired and interfering with their ability to ... the scientist whose original research led to the drug ...
Cached Medicine News:Health News:Reformulated imatinib eliminates morphine tolerance in lab studies 2Health News:Telomere failure, telomerase activation drive prostate cancer progression 2Health News:Telomere failure, telomerase activation drive prostate cancer progression 3Health News:Cedars-Sinai awarded $2.5 million to study potential new drug treatments for Alzheimer's disease 2Health News:15% of U.S. Surgeons Report Drinking Problems in Survey 2Health News:15% of U.S. Surgeons Report Drinking Problems in Survey 3Health News:15% of U.S. Surgeons Report Drinking Problems in Survey 4Health News:UC Davis MIND Institute researchers to present on autism at AAAS Annual Meeting in Vancouver 2Health News:Alzheimer's drugs may have adverse side effects 2
... The full color LCD ... familiar joystick controls, enable any ... make quick and accurate measurements.,Measurement ... the color screen, and results ...
... Patients who need punctal ... dry eye relief. They also ... be as comfortable and as ... why Alcon punctal plugs are ...
... to diagnostic images and reports, the powerful ... scaled to meet the needs of virtually ... Web PACS system allows clinicians, referring physicians, ... view images and information on-site or at ...
... SonoAce 9900 is a ... ultrasound system, with an ... DICOM compatible, designed for ... imaging, obstetrics, gynecology, perinatology, ...
Medicine Products: